Trial Profile
Phase 3, open-label, multi-center, double-blind, randomized, parallel group study efficacy and safety of fixed combination torcetrapib/atorvastatin, administered once daily compared to fixed combination ezetimibe/simvastatin for 6 weeks in subjects with dyslipidemia
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 05 Dec 2006
Price :
$35
*
At a glance
- Drugs Ezetimibe/simvastatin (Primary) ; Torcetrapib/atorvastatin (Primary)
- Indications Lipid metabolism disorders
- Focus Biomarker; Registrational; Therapeutic Use
- Sponsors Pfizer
- 05 Dec 2006 Status change
- 18 Aug 2006 New trial record.